07.27.17
Biogen
2Q Revenues: $3.1 billion (+6%)
2Q Earnings: $863 million (-18%)
YTD Revenues: $5.9 billion (+5%)
YTD Earnings: $1.6 billion (-20%)
Comments: Growth was driven by MS revenues, which increased 5%. This included a 13% increase in TECFIDERA to $1.1 billon. SPINRAZA revenues grew to $203 million and BENEPALIT revenues increased to $89 million in the quarter. Avonex sales were down 8% to $691 million. Tysabri sales were flat at $496 million. Plegridy sales were $133 million, up 8%. Biosimilar sales were $91 million in the quarter, up from $15 million 2Q16. In 1Q17, Biogen completed the separation of its global hemophilia business into a new company, known as Bioverativ. The 15% increase in total revenues excludes all hemophilia revenues from 2Q16. Hemophilia revenues include ELOCTATE and ALPROLIX product revenues as well as royalty and contract manufacturing revenue related to Sobi.
2Q Revenues: $3.1 billion (+6%)
2Q Earnings: $863 million (-18%)
YTD Revenues: $5.9 billion (+5%)
YTD Earnings: $1.6 billion (-20%)
Comments: Growth was driven by MS revenues, which increased 5%. This included a 13% increase in TECFIDERA to $1.1 billon. SPINRAZA revenues grew to $203 million and BENEPALIT revenues increased to $89 million in the quarter. Avonex sales were down 8% to $691 million. Tysabri sales were flat at $496 million. Plegridy sales were $133 million, up 8%. Biosimilar sales were $91 million in the quarter, up from $15 million 2Q16. In 1Q17, Biogen completed the separation of its global hemophilia business into a new company, known as Bioverativ. The 15% increase in total revenues excludes all hemophilia revenues from 2Q16. Hemophilia revenues include ELOCTATE and ALPROLIX product revenues as well as royalty and contract manufacturing revenue related to Sobi.